首页 › 基金 › Soleus Capital Management, L.P. › JBIO

Soleus Capital Management, L.P. 对 JBIO 的持仓历史

JADE BIOSCIENCES INC · 医疗保健

Soleus Capital Management, L.P. 在 Q3 2026 的 13F 申报中披露持有 JBIO(JADE BIOSCIENCES INC)1,170,928 股,市值约 US$16.5M,约占其申报组合的 0.58%,在其申报持仓中市值排名第 40 位。 Soleus Capital Management, L.P. 最近 6 个申报季度中有 6 个季度披露了 JBIO 持仓,最早可追溯至 Q2 2025。

最新持仓 (Q3 2026)1.17M 股
申报持仓市值$16.45M
组合权重0.58%
首次申报Q2 2025
最近变动减持
更新于2026-11-17

最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR

Soleus Capital Management, L.P. 对 JBIO 的持仓演变

Soleus Capital Management, L.P. 于 Q2 2025 首次披露 JBIO 持仓:796,744 股(约 US$8.0M)。 该持仓在 Q2 2026 达到峰值 1,550,690 股,市值约 US$34.5M。 在 6 次申报中,Soleus Capital Management, L.P. 1 次增持、1 次减持、3 次保持不变。 最近一期申报(Q3 2026)显示持股 1,170,928 股、市值约 US$16.5M,环比减持 -379,762 股。。 持仓曾出现大幅变动:Q2 2026 增持约 95% (随后一个季度股价下跌 37%)。

逐季持仓明细

季度股数金额变化
Q2 2025 796.74K $7.96M 新进
Q3 2025 796.74K $6.88M 持有
Q4 2025 796.74K $12.29M 持有
Q1 2026 796.74K $11.19M 持有
Q2 2026 1.55M $34.46M 增持
Q3 2026 1.17M $16.45M 减持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 JBIO 与 13F 数据

JBIO(JADE BIOSCIENCES INC)属于医疗保健行业。我们追踪的基金中还有 81 只申报持有 JBIO,申报仓位最大的包括:Paradigm Biocapital Advisors LP (US$85.0M), Fairmount Funds Management LLC (US$64.0M), Bellevue Group AG (US$60.3M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 JBIO 的基金

查看 JBIO 的全部基金持有人 →

常见问题

How long has Soleus Capital Management, L.P. held JBIO?

Soleus Capital Management, L.P. has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.

What is Soleus Capital Management, L.P.'s current position in JBIO?

As of Q3 2026, Soleus Capital Management, L.P. holds 1.17M shares of JBIO (JADE BIOSCIENCES INC), valued at $16.45M, representing 0.58% of its reported portfolio and ranking #40.

Has Soleus Capital Management, L.P. been buying or selling JBIO?

In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. reduced its position in JBIO. The position peaked in Q2 2026 at 1.55M shares.

Which other funds hold JBIO?

Other major institutional holders of JBIO include Paradigm Biocapital Advisors LP, Fairmount Funds Management LLC, Bellevue Group AG, among 81 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.